Form 4: Elevance Health CEO's Recent Equity Transactions

Elevance Health President and CEO Gail Boudreaux reported the acquisition of restricted stock units and stock options, alongside dispositions to cover tax liabilities.

Summary

• Gail Boudreaux, President and CEO of Elevance Health, Inc. (ELV), reported several transactions involving the company's common stock and derivative securities.
• On March 2, 2026, 6,713 shares of common stock were disposed of at $294.07 per share to satisfy tax liabilities related to the vesting of previously granted restricted stock.
• On March 2, 2026, 16,153 restricted share units (RSUs) were acquired at a price of $0. These RSUs will vest in three installments: 5,384 shares each on March 2, 2027, and March 2, 2028, and 5,385 shares on March 2, 2029.
• Also on March 2, 2026, 10,527 performance-based restricted share units were acquired at a price of $0, with restrictions lapsing on March 2, 2026.
• On March 3, 2026, an additional 1,736 shares of common stock were disposed of at $284.03 per share for tax liability related to vesting restricted stock.
• Following these transactions, Boudreaux directly beneficially owns 169,251 shares of common stock.
• An indirect beneficial ownership of 60 shares is held in a spouse's revocable trust.
• On March 2, 2026, 63,818 employee stock options were acquired at an exercise price of $294.07 and an acquisition price of $0. These options become exercisable in three annual installments starting March 2, 2027, and expire on March 2, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting routine executive compensation that aligns management's interests with long-term shareholder value, without indicating any unusual or concerning activity.

Positives

• Acquisition of 16,153 restricted share units and 10,527 performance-based restricted share units aligns executive interests with long-term shareholder value.
• Grant of 63,818 employee stock options provides a future incentive for performance and stock price appreciation.
• The transactions reflect routine executive compensation, indicating stability in management incentives.

Negatives

• Dispositions of 6,713 shares at $294.07 and 1,736 shares at $284.03 were solely for tax withholding purposes upon vesting of previously granted restricted stock, not a discretionary sale for profit.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, focusing solely on insider equity transactions.

Industry Context

StockSavvy.ai notes that these types of equity grants and tax-related dispositions are standard practice in executive compensation packages across the healthcare industry. Such compensation structures are designed to align the interests of top executives with long-term shareholder value, a common trend among large-cap health insurers and managed care organizations like UnitedHealth Group or Cigna.

Comparison to Industry Standards

• The structure of granting restricted stock units (RSUs) and stock options is a common practice for executive compensation in large public companies, including peers like UnitedHealth Group (UNH) and Humana (HUM).
• The disposition of shares to cover tax liabilities upon vesting is a standard mechanism for executives to manage their tax obligations without needing to sell additional shares on the open market.
• The multi-year vesting schedule for RSUs and options is typical, promoting long-term retention and performance alignment, similar to compensation plans observed at major healthcare providers and insurers.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's financial interests with the company's stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: While not directly impacting all employees, executive compensation structures can influence overall company culture and compensation philosophy.

Next Steps

• Vesting of 5,384 restricted share units on March 2, 2027.
• First installment of 21,272 employee stock options becomes exercisable on March 2, 2027.
• Vesting of 5,384 restricted share units on March 2, 2028.
• Second installment of 21,273 employee stock options becomes exercisable on March 2, 2028.
• Vesting of 5,385 restricted share units on March 2, 2029.
• Third installment of 21,273 employee stock options becomes exercisable on March 2, 2029.
• Employee stock options expire on March 2, 2036.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation, including grants of restricted stock units and stock options, and dispositions for tax purposes. Such transactions are standard and do not typically indicate a fundamental shift in the company's prospects or warrant a change in investment recommendation based solely on this filing. It reinforces the alignment of executive incentives with long-term company performance.

Keywords

Elevance Health, ELV, Form 4, Insider Transaction, Gail Boudreaux, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant, Tax Withholding